Chordoma Disease Companies

January 2024:A Phase II clinical trial evaluating the safety and efficacy of ibrutinib (Calquence) in combination with everolimus (Afinitor) for advanced Chordoma is underway at MD Anderson Cancer Center.

December 2023:A study published in the Journal of Clinical Oncology suggests that immunotherapy with pembrolizumab (Keytruda) may offer promising results in patients with advanced Chordoma.

November 2023:Researchers from the University of California San Francisco announce the identification of a new genetic mutation associated with Chordoma, potentially paving the way for targeted therapy development.

October 2023:Blue Sphere Corporation receives orphan drug designation from the FDA for its investigational drug, BLS-804, for the treatment of Chordoma.

September 2023:Sanofi partners with the Chordoma Foundation to support research and development efforts for Chordoma treatment.

August 2023:The Chordoma Foundation launches a new research initiative focused on identifying biomarkers for early diagnosis of Chordoma.

List of Chordoma Disease Key Companies in the Market

• AstraZeneca plc (U.K.)


• Amgen, Inc. (U.S.)


• Actavis plc (U.S.)


• Bristol-Myers Squibb and Company (U.S.)


• Celgene Corporation (U.S.)


• Eli Lilly and Company (U.S.)


• Hoffmann-La Roche AG (Switzerland)


• GlaxoSmithKline plc (UK)


• Novartis International AG (Switzerland)


• Pfizer, Inc. (U.S.)


• Sanofi S.A. (France)


• Debiopharm Group (Switzerland)


• Bayer AG (Germany)


• Johnson & Johnson (U.S.)


• Merck & Co., Inc. (U.S.)


• Optivus Proton Therapy, Inc. (U.S.)


• ProCure Treatment Centers, Inc. (U.S.)


• Varian Medical Systems, Inc.(U.S.)


• Amura Holdings Ltd. (U.S.)


• Catena pharmaceuticals Inc. (U.S.)


• Celldex therapeutics Inc. (U.S.)


• Eckert & Ziegler BEBIG (Germany)


• Infinity Pharmaceuticals (U.S.)


• Medivir AB (Sweden)


• Merrion Pharmaceuticals Plc. (U.S.).